Loading Events

IDEAYA Biosciences Investor R&D Day: Highlighting IDEAYA’s Synthetic Lethality Pipeline – Scientific Insights and Future Clinical Development Plans

DATE: December 4, 2023

About The Event

Join IDEAYA Biosciences for a virtual Investor R&D day featuring GSK and a KOL, showcasing scientific insights and clinical development opportunities across IDEAYA’s synthetic lethality pipeline, including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, and the GSK partnered programs.

In addition, IDEAYA will highlight its next generation initiatives in MTAP-deletion, including a wholly-owned program where a development candidate nomination is targeted in 2024, further advancing IDEAYA’s multi-pronged strategy. The IDEAYA Investor R&D Day Webcast agenda will be the following:

Agenda Topics

  • The Synthetic Lethality Paradigm
    • ­ IDEAYA Vision, Strategy and Pipeline (Yujiro S. Hata, CEO)
  • Computational Drug Discovery
    • ­ Overview of Current Approaches at IDEAYA (Mike White, CSO)
  • IDE161 Clinical Data and Program Updates (Timothy Yap, MD Anderson)
  • Emerging Therapeutic Opportunities for MTAP-deletion
    • ­ IDEAYA’s Multiple-Pronged Strategy (Mike White, CSO; Darrin Beaupre, CMO)
  • IDEAYA and GSK Partnership
    • ­ Pol Theta Helicase and Werner Helicase Programs (Ramon Kemp, GSK)

Key Opinion Leader Presenters

  • Timothy Yap, M.D., Associate Professor, Department for Investigational Cancer Therapeutics and Department of Thoracic/Head and Neck Medical Oncology, Medical Director, Institute for Applied Cancer Science, Associate Director of Translational Research, Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center
  • Ramon Kemp, Ph.D., Vice President, Head, Oncology EDL, Interim Head, Oncology MDL, GSK

A live analyst Q&A will follow the formal presentations.